[Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Biopsia líquida en oncología: Consenso de la Sociedad Española de Oncología Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP).
Biopsia líquida
CtDNA
Genomic profiling
Liquid biopsy
Medicina de precisión
Oncology
Oncología
Perfil genómico
Precision medicine
ctADN
Journal
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
ISSN: 1988-561X
Titre abrégé: Rev Esp Patol
Pays: Spain
ID NLM: 100885154
Informations de publication
Date de publication:
Historique:
received:
27
09
2019
revised:
27
11
2019
accepted:
09
12
2019
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2021
Statut:
ppublish
Résumé
The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is increasing considerably. The diagnosis of these genomic alterations can lead to tailoring of treatment, at the onset of disease or during progression, as well as providing additional, predictive information on the efficacy of immunotherapy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore required for molecular stratification, such as liquid biopsy. This technique enables the evaluation of the tumour genomic profile dynamically and as well as capturing intra-patient genomic heterogeneity. To date, there are several diagnostic techniques available for use in liquid biopsy, each with different precision and performance levels. The objective of this consensus statement of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) is to evaluate the viability and effectiveness of the different methodological approaches of liquid biopsy in cancer patients, and the potential application of this method to current clinical practice. The experts contributing to this consensus statement agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures to ensure reproducibility and to generate structured and accessible clinical reports. It is essential to appoint multidisciplinary tumour molecular committees to oversee these processes and to enable the most suitable therapeutic decisions for each patient according to the genomic profile.
Identifiants
pubmed: 33012494
pii: S1699-8855(20)30014-3
doi: 10.1016/j.patol.2019.12.001
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
spa
Sous-ensembles de citation
IM
Pagination
234-245Informations de copyright
Copyright © 2020 Sociedad Española de Anatomía Patológica. Publicado por Elsevier España, S.L.U. All rights reserved.